|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6429186B1
(en)
|
1991-05-10 |
2002-08-06 |
Genentech, Inc. |
Ligand antagonists for treatment of breast cancer
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
AU3895299A
(en)
|
1998-05-12 |
1999-11-29 |
Wen Y Chen |
Use of anti-prolactin agents to treat proliferative conditions
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US6867187B2
(en)
|
2000-12-22 |
2005-03-15 |
Trustees Of The University Of Pennsylvania |
Composition and method for modulating somatolactogenic function
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
WO2005058232A2
(en)
|
2003-12-11 |
2005-06-30 |
Tercica, Inc. |
Methods and compositions for the treatment of prolactin-receptor related disorders
|
|
US8754031B2
(en)
|
2004-03-08 |
2014-06-17 |
Oncolix, Inc. |
Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
|
|
US7422899B2
(en)
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
|
US20070092920A1
(en)
|
2005-10-24 |
2007-04-26 |
Clevenger Charles V |
Serum Prolactin Binding Protein in Epithelial Carcinoma
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
KR101359081B1
(ko)
|
2006-06-27 |
2014-02-05 |
톰슨 라이센싱 |
성능 인식 ｐ２ｐ 콘텐트 온 디맨드
|
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
WO2009010398A1
(en)
|
2007-07-18 |
2009-01-22 |
Novo Nordisk A/S |
Stabilized prolactin receptor antagonists
|
|
UA108598C2
(xx)
|
2008-04-30 |
2015-05-25 |
|
Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
|
WO2012136519A1
(en)
|
2011-04-06 |
2012-10-11 |
Bayer Pharma Aktiengesellschaft |
Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer
|
|
EP2530089A1
(en)
|
2011-06-03 |
2012-12-05 |
Bayer Pharma Aktiengesellschaft |
Neutralising prolactin receptor antibody Mat3 and its therapeutical use
|
|
CN102746402A
(zh)
|
2012-07-09 |
2012-10-24 |
南京医科大学 |
全人源抗人催乳素受体单链抗体及其应用
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
DK2935331T3
(en)
|
2012-12-24 |
2018-06-06 |
Abbvie Inc |
PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
|
|
EP3964237B1
(en)
|
2013-03-15 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
UY35460A
(es)
|
2013-03-15 |
2014-10-31 |
Bayer Healthcare Llc |
Formulaciones de anticuerpos anti-receptor de prolactina
|
|
TWI641620B
(zh)
*
|
2013-08-21 |
2018-11-21 |
再生元醫藥公司 |
抗－ｐｒｌｒ抗體及其用途
|
|
US9545451B2
(en)
*
|
2013-08-21 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-PRLR antibodies and methods for killing PRLR-expressing cells
|
|
AU2014311361B2
(en)
|
2013-08-26 |
2018-11-29 |
Regeneron Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
|
|
CA2978340C
(en)
|
2015-03-27 |
2024-05-28 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|